Evaluation of Viral Load as a Triage Strategy With Primary High-Risk Human Papillomavirus Cervical Cancer Screening

被引:39
|
作者
Luo, Hongxue [1 ,2 ]
Belinson, Jerome L. [3 ,4 ]
Du, Hui [1 ,2 ]
Liu, Zhihong [1 ,2 ]
Zhang, Lijie [1 ,2 ]
Wang, Chun [1 ,2 ]
Qu, Xinfeng [4 ]
Pretorius, Robert G. [5 ]
Wu, Ruifang [1 ,2 ]
机构
[1] Peking Univ, Dept Obstet & Gynecol, Shenzhen Hosp, 1120 Lianhua Rd, Shenzhen 518036, Peoples R China
[2] Shenzhen Tech Res & Dev Ctr Gynecolig Oncol, Shenzhen, Peoples R China
[3] Cleveland Clin, Gynecol Oncol Div, Womens Hlth Inst, Cleveland, OH 44106 USA
[4] Prevent Oncol Int, Cleveland Hts, OH USA
[5] Kaiser Permanente, Dept Obstet & Gynecol, Fontana, CA USA
关键词
human papillomavirus; viral load; Hybrid Capture 2; cytology; cervical cancer screening; HYBRID CAPTURE 2; LESIONS; DNA; PREVENTION; GRADE; WOMEN; CYTOLOGY; DETECT; HPV16;
D O I
10.1097/LGT.0000000000000277
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The aim of the study was to evaluate the human papillomavirus (HPV) viral load combined with cytology as a secondary screening strategy after primary HPV screening. Materials and Methods: The data referring to direct Hybrid Capture 2 (HC2), cytology, and histology from Shenzhen Cervical Cancer Screening Trial II were re-analyzed to determine the correlation between viral load and cervical lesions. In addition, algorithms using different viral loads as cut points for immediate colposcopy plus cytology triage were compared with several recommended or controversial primary screening methods. Results: A total of 8,556 women with a mean age of 38.9 years were included in the analysis, of which 13.67% tested high-risk HPV positive with a prevalence of 2.72% for cervical intraepithelial neoplasia 2+ (CIN 2+) and 1.65% for CIN 3+. A significant correlation was observed between increasing relative light units/control (RLU/CO) values and worsening cervical lesions. The mean RLU/CO values for negative, CIN 1, CIN 2, CIN 3, and cancer were 6.86, 119.43, 410.90, 449.39, and 853.26, respectively. A larger proportion of HPV infections with relative high viral load (>= 10 RLU/CO) were found in higher-grade lesions. The algorithm using 10 or greater RLU/CO as cut point for immediate colposcopy followed by triage cytology for the other positive (>= 1 < 10 RLU/CO) had sensitivity of 93.13%/96.45% and specificity of 92.32%/91.44% for CIN 2+/3+, and the colposcopy referral rate was 10.00%. Conclusions: Human papillomavirus viral load level is positively associated with cervical lesion grade. Ten relative light units/control or greater is a viable threshold for immediate colposcopy whereas 1 or greater or less than 10 RLU/CO is advised to reflex cytology for optimizing sensitivity and specificity, as well as referral rates.
引用
收藏
页码:12 / 16
页数:5
相关论文
共 50 条
  • [41] Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Quebec, Canada
    Vijayaraghavan, Arthi
    Efrusy, Molly B.
    Mayrand, Marie-Helene
    Santas, Christopher C.
    Goggin, Patricia
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2010, 101 (03): : 220 - 225
  • [42] Re: Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study
    Song, Fangbin
    Yan, Peisha
    Wu, Ruifang
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2020, 127 (13) : 1713 - 1714
  • [43] High-risk Human Papillomavirus in a screening population
    Schledermann, D. E.
    Rasmussen, M.
    Mose, L.
    APMIS, 2011, 119 : 18 - 19
  • [44] Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus
    Luckett, Rebecca
    Mogowa, Neo
    Li, Howard J.
    Erlinger, Adrienne
    Hacker, Michele R.
    Esselen, Katharine
    Feldman, Sarah
    Shapiro, Roger
    Morroni, Chelsea
    Ramogola-Masire, Doreen
    OBSTETRICS AND GYNECOLOGY, 2019, 134 (04): : 840 - 849
  • [45] Human papillomavirus testing for primary cervical cancer screening
    Meijer, CJLM
    Rozendaal, L
    vanderLinden, JC
    Helmerhorst, TJM
    Voorhorst, FJ
    Walboomers, JMM
    NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, 1997, : 338 - 347
  • [46] Human papillomavirus testing for primary cervical cancer screening
    Grce, Magdalena
    Davies, Philip
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (05) : 599 - 605
  • [47] Primary cervical screening with high risk human papillomavirus testing: observational study
    Rebolj, Matejka
    Rimmer, Janet
    Denton, Karin
    Tidy, John
    Mathews, Christopher
    Ellis, Kay
    Smith, John
    Evans, Chris
    Giles, Thomas
    Frew, Viki
    Tyler, Xenia
    Sargent, Alexandra
    Parker, Janet
    Holbrook, Miles
    Hunt, Katherine
    Tidbury, Penny
    Levine, Tanya
    Smith, David
    Patnick, Julietta
    Stubbs, Ruth
    Moss, Sue
    Kitchener, Henry
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 364
  • [48] Human papillomavirus testing for primary cervical cancer screening
    Carolyn D. Runowicz
    Stephanie Garozzo
    Current Oncology Reports, 2008, 10
  • [49] Human Papillomavirus Testing for Primary Cervical Cancer Screening
    Runowicz, Carolyn D.
    Garozzo, Stephanie
    CURRENT ONCOLOGY REPORTS, 2008, 10 (06) : 533 - 537
  • [50] Human papillomavirus testing for primary cervical cancer screening
    Cuzick, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (01): : 108 - 109